secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001193125-22-216844
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M
--------------------------------------------------------------------------

- FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.
- Net loss $18.3M (vs $1.5M in Q2 2021), includes $3.7M impairment charge.
- Cash and equivalents $118.7M; expected to fund operations into 2024.
- PRECISION 1 trial (TSC1/TSC2) enrollment ongoing; preliminary data expected 1H23.
- Permanent J-code (J9331) for FYARRO effective July 1, 2022 from CMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/0001193125-22-216844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/d349452d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-216844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer